Lee Hyunju, Cha Jung Hwa, Nahm Moon H, Burton Robert L, Kim Kyung-Hyo
Department of Pediatrics, Ewha Womans University School of Medicine, Seoul, Korea.
BMC Infect Dis. 2013 Oct 10;13:474. doi: 10.1186/1471-2334-13-474.
We investigated the immune response to serogroup 6 with the opsonophagocytic killing assay (OPKA) in children aged 12-23 months of age after immunization with the 7-valent pneumococcal conjugate vaccine (PCV7) containing serotype 6B.
Blood samples were obtained from 59 children who had blood sampling for medical examination. Immunization status against PCV7 was confirmed by immunization records and samples were categorized according to immunization status into a booster, primary, or control group. The OPKA was performed for serotypes 6A, 6B, 6C, and 6D.
Subjects with no previous PCV7 immunization history showed opsonic activity for serogroup 6 in 5-30% (according to serotype). In subjects vaccinated with a 3-dose primary series, 81% showed opsonic activity for serotypes 6B and 6D, and 29% showed opsonic activity for serotypes 6A and 6C. Among subjects vaccinated with a booster dose, all subjects had opsonic activity against serotype 6B. Subjects in the booster group with opsonic activity against serotypes 6A, 6C, and 6D were 100%, 78%, and 89%, respectively.
In subjects aged 12-23 months, an immune response is elicited after a primary series of immunizations with PCV7 for serotypes 6B and 6D, and a booster dose enhances a cross reactive immune response against serotypes 6A, 6C and 6D.
我们采用调理吞噬杀菌试验（OPKA）研究了12至23个月大儿童在接种含6B血清型的7价肺炎球菌结合疫苗（PCV7）后对6血清群的免疫反应。
从59名因医学检查而采血的儿童中获取血样。通过免疫记录确认PCV7的免疫状态，并根据免疫状态将样本分为加强免疫组、初次免疫组或对照组。对6A、6B、6C和6D血清型进行OPKA检测。
既往无PCV7免疫史的受试者对6血清群显示出5%至30%（根据血清型）的调理活性。在接种3剂基础免疫系列的受试者中，81%的人对6B和6D血清型显示出调理活性，29%的人对6A和6C血清型显示出调理活性。在接种加强剂量的受试者中，所有受试者对6B血清型均有调理活性。加强免疫组中对6A、6C和6D血清型有调理活性的受试者分别为100%、78%和89%。
在12至23个月大的受试者中，PCV7基础免疫系列接种后可引发对6B和6D血清型的免疫反应，加强剂量可增强对6A、6C和6D血清型的交叉反应免疫反应。
